Summary

A year after their initial presentation, the findings of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial continued to generate debate and uncertainty. This article helps provide clarity about the trial results and their implications for specific subgroups of patients.